Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Georgetown University
Study ID
NCT00020748
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of epirubicin plus irinotecan in treating patients who have advanced cancer.

Key Dates

Start date
Aug 31, 2000
Status verified
Jan 2005
Primary completion
Oct 31, 2004
Completion
Oct 31, 2004

Study Design

Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Lombardi Cancer Center at Georgetown University Medical CenterWashington D.C.District of Columbia20007-

Find similar trials in Washington D.C., DC

By research site
Lombardi Cancer Center at Georgetown University Medical Center· Washington D.C., DC

Related Studies